Oncology

News

Novartis closes on EU approval for breast cancer drug Piqray

Novartis has moved nearer to claiming approval for its PI3K inhibitor Piqray for breast cancer in the EU, one of a crop of new drugs that the company thinks have blockbuster sa

News

AZ nabs a positive study for Imfinzi plus tremelimumab in li...

After a long run of trial disappointments, AstraZeneca is celebrating a win for its immuno-oncology combination of Imfinzi plus tremelimumab in advanced liver cancer.

Oncology

ASCO 2020 virtual annual meeting - day 3

Our live coverage from this year’s slimmed down, virtual version of the American Society of Clinical Oncology (ASCO) annual meeting continues at 8am (ET) as we move into the third and final

Oncology

ASCO 2020 virtual annual meeting - day 2

Our live coverage from this year’s slimmed down, virtual version of the American Society of Clinical Oncology (ASCO) annual meeting continues at 8am (ET) as we move into day 2 of the oncolo

News

AstraZeneca's (AZ) Tagrisso (osimertinib)

Given after surgery, AZ’s Tagrisso prevents lung cancer comi...

AstraZeneca opened its account at this year’ virtual ASCO meeting with data showing that adjuvant (post-surgery) use of Tagrisso delays the recurrence of EGFR-positive non-smal

News

Merck & Co's Keytruda outperforms chemo in MSI-High colorect...

Merck & Co’s Keytruda (pembrolizumab) immunotherapy has outperformed standard of care in untreated colorectal cancer with certain mutations, offering patients a single-agent therapy opt

Novartis closes on EU approval for breast cancer drug Piqray

AZ nabs a positive study for Imfinzi plus tremelimumab in li...

ASCO 2020 virtual annual meeting - day 3

ASCO 2020 virtual annual meeting - day 2

Given after surgery, AZ’s Tagrisso prevents lung cancer comi...

Merck & Co's Keytruda outperforms chemo in MSI-High colorect...

MSD takes a $400m bite of SciBrunch's KRAS drug

Discover a new era of healthcare panel engagement: Grounded ...

Oncology

Editor's Picks